Cargando…
Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
Autores principales: | Gooderham, Melinda J., Chu, Chia-Yu, Rojo, Ricardo, Valdez, Hernan, Biswas, Pinaki, Cameron, Michael C., Feeney, Claire, Encinas, Gerardo A., Peeples-Lamirande, Kathleen, Cappelleri, Joseph C., Myers, Daniela E., DiBonaventura, Marco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361901/ https://www.ncbi.nlm.nih.gov/pubmed/34409391 http://dx.doi.org/10.1016/j.jdin.2021.05.004 |
Ejemplares similares
-
Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021) -
Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021) -
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020) -
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial
por: Simpson, Eric L., et al.
Publicado: (2023) -
Early Itch Response with Abrocitinib Is
Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic
Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE
Trial
por: Ständer, Sonja, et al.
Publicado: (2022)